EJPMR, 2026, 13(11), 408-414 **Research Article** **Impact Factor: 8.158**

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

ISSN (O): 2394-3211
ISSN (P): 3051-2573
Coden USA: EJPMAG

RESEARCH ARTICLE ON REGULATORY REQUIREMENTS FOR CLINICAL TRIAL APPROVAL PROCESS AS PER CDSCO IN COMPARISION WITH NETHERLAND

***Dr. P. Ashok Kumar, Arpitha P., Bhavana C. N., Bhavyashree D. N., Chandana M., Thejashwini H. J.**

Department of Regulatory Affairs, Sree Siddaganga College of Pharmacy. 1st Left Cross, 3rd Block, Mahalakshmi Nagar, Near Railway Gate, 80 Feet Road, Batwadi, Tumkur-572103. Karnataka (India).

***Corresponding Author: Dr. P. Ashok Kumar**

Department of Regulatory Affairs, Sree Siddaganga College of Pharmacy. 1st Left Cross, 3rd Block, Mahalakshmi Nagar, Near Railway Gate, 80 Feet Road, Batwadi, Tumkur-572103. Karnataka (India).

DOI: https://doi.org/10.5281/zenodo.23803859

How to cite this Article: *Dr. P. Ashok Kumar, Arpitha P., Bhavana C. N., Bhavyashree D. N., Chandana M., Thejashwini H. J. (2026). Research Article on Regulatory Requirements For Clinical Trial Approval Process As Per Cdsco In Comparision With Netherland. European Journal of Pharmaceuticaland Medical Research, 13(11), 408–414.

This work is licensed under Creative Commons Attribution 4.0 International license.

Article Received on 04/10/2026 **Article Revised on 25/10/2026** **Article Published on 01/11/2026**

ABSTRACT

Clinical trials provide evidence on the safety and efficacy of medicines and require regulatory oversight to protect participants and ensure ethical research. In India, clinical trials are regulated by CDSCO, the Central Licensing Authority, NDCTR 2019, Ethics Committees, and CTRI. Applications are submitted through the SUGAM portal and undergo regulatory and ethical review before approval. Compliance with GCP, informed consent, safety reporting, monitoring, and trial completion requirements is essential.In the Netherlands, clinical trials involving medicinal products are governed mainly by the European Union Clinical Trials Regulation (EU) No. 536/2014 and are submitted through the Clinical Trials Information System (CTIS). Ethical oversight is provided by the Central Committee on Research Involving Human Subjects (CCMO) or accredited Medical Research Ethics Committees (MRECs), while the Medicines Evaluation Board (MEB/CBG-MEB) contributes to medicinal-product assessment.The comparison demonstrates that both countries emphasize participant safety, ethical review, scientific validity, GCP compliance, and continuous safety monitoring. However, their regulatory structures differ, with India following a predominantly national framework and the Netherlands operating within a harmonized European regulatory system through CTIS. Understanding these similarities and differences is important for investigators and sponsors planning clinical trials across jurisdictions. Effective regulatory oversight ultimately requires scientific rigor, independent ethical evaluation, transparent procedures, efficient electronic submission systems, risk-based monitoring, and continuous protection of trial participants.

KEYWORDS: Clinical trials, CDSCO, CCMO, MEB, CTIS.

INTRODUCTION

CLINICAL TRIAL: Clinical trials are systematic research studies conducted in human participants to evaluate the safety, efficacy, and quality of new drugs, vaccines, or medical products before they are approved for marketing. In India, the approval and regulation of clinical trials are controlled by the Central Drugs Standard Control Organization (CDSCO) under the supervision of the Drugs Controller General of India (DCGI). The clinical trial approval process is regulated according to the New Drugs and Clinical Trials Rules (NDCTR), 2019 and follows the principles of Good Clinical Practice (GCP).

Phases of Trials

Phase I: Tests safety, tolerability, and appropriate dose in a small group.
Phase II: Evaluates effectiveness and further assesses safety in patients.
Phase III: Confirms efficacy and safety in a large patient population and compares with standard treatment/placebo.
Phase IV: Post-marketing studies monitor long-term safety and rare adverse effects.[1]

Table no. 1: The phases, types and nature of clinical trial studies.

Clinical trial phase	Type of the study	Nature of study
Phase 0	Exploratory	Examines too low (1/100th) concentrations (micro-dosing) of the drug for less time. Study the pharmacokinetics and determine the dose for phase I studies. Previously done in animals but now it is carried out in humans.
Phase I, Phase Ia, Phase Ib	Non-therapeutic trial	Around <50 healthy subjects are recruited. Establishes a safe dose range, and the MTD. Examines the pharmacokinetic and pharmacodynamic effects. Usually single-center studies. Phase Ia: SAD, and MTD. Duration of one week to several months depending on the trial and includes 6-8 groups of 3-6 participants. Phase Ib: MAD and the dose is gradually narrowed down. Three groups of 8 individuals each.
Phase II, Phase IIa, Phase IIb	Exploratory trial	Recruiting around 5-100 patients of either sex. Examines the effective dosage and the therapeutic effects on patients. It decides the therapeutic regimen and drug-drug interactions. Usually, multicentre studies. Phase IIa: Decides the drug dosage, includes 20-30 patients, and takes up to weeks/months. Phase IIb: Studies dose-response relationship, drug-drug interactions, and comparison with a placebo.
Phase III	Therapeutic confirmatory trial	More than 300 patients (up to 3000) of either sex are recruited in this study and are multicentric trials. Pre-marketing phase examines the efficacy and the safety of the drug. Comparison of the test drug with the placebo/standard drug. Adverse drug reactions/adverse events are noted. Initiate the process of NDA with appropriate regulatory agencies like the FDA.
Phase IV	Post-approval study	After approval/post-licensure and post-marketing studies/surveillance studies. Following up on the patients for an exceptionally long time for potential adverse reactions and drug-drug interactions.

Table no. 2: Clinical trial designs, their advantages and disadvantages.

Trial design type	Type of the study	Nature of study	Advantages/disadvantages
Parallel	Randomized	This is the most frequent design wherein each arm of the study group is allocated a particular treatment (placebo (an inert substance)/therapeutic drug)	The placebo arm does not receive the trial drug, so may not get the benefit of it
Crossover	Randomized	The patient in this trial gets each drug and the patients serve as a control themselves	Avoids participant bias in treatment and requires a small sample size. This design is not suitable for research on acute diseases.
Factorial	Non-randomized	Two or more interventions on the participants and the study can provide information on the interactions between the drugs	The study design is complex
Randomized withdrawal approach	Randomized	This study evaluates the time/duration of the drug therapy	The study uses a placebo to understand the efficacy of a drug in treating the disease
Matched pairs	Post-approval study	Recruit patients with the same characteristics	Less variability

REGULATORY BODY OF INDIA

Central Drug Standard Control Organization (CDSCO) The Central Drugs Standard Control Organization (CDSCO) is the National Regulatory Authority in India. Its equivalent counterparts elsewhere include the United States Food and Drug Administration (US FDA), Health Canada and the European Medicines Agency. CDSCO is an arm of the Ministry of Health and Family Welfare, Government of India. Its mission is to safeguard and enhance public health by assuring the safety, efficacy and quality of drugs, cosmetics and medical devices.

The Drugs Controller General of India (DCGI) is an official of the CDSCO who is the final regulatory authority for the approval of clinical trials in the country. His ambit, in addition, also extends to inspections of trial sites, inspections of sponsors of clinical research and manufacturing facilities in the country, oversight of the

Central Drugs Testing Laboratory (Mumbai) and the Regional Drugs Testing Laboratory as also heading the Indian Pharmacopeia Commission among various other roles, responsibilities and functions.[1,2]

Figure no 1: CDSCO Logo.

Organisation of CDSCO

The Central Drugs Standard Control Organization (CDSCO) is headed by the Drugs Controller General of India (DCGI) and functions under the Ministry of Health & Family Welfare, Government of India.



Figure no. 2: Organization of CDSCO.

Functions of CDSCO

- Approval of new drugs and clinical trials.
- Important registration and licensing.
- License approving of blood bank, LVPs, vaccines, r-DNA products and some medical devices (CLAA Scheme).
- Amendment to D and C act and rules.
- Banning of drugs and cosmetics.
- Grant of test license, personal license, NOCs for export.
- Testing of the new drugs
- Oversight and market survival in through inspectorate of centre Over and above the state authority.[1]

REGULATORY BODY OF NETHERLANDS

CENTRAL COMMISSIE MENSGEBONDEN ONDERZOEK(CCM0)

The primary regulatory authorities for clinical trial in the Netherland are the Central Committee on research involving human subjects(CCMO) and Medicines Evaluation Board (MEB)which operates alongside accredited local ethics committees. The Central Committee on Research Involving Human Subjects (CCMO) was established on the basis of section 14 of the Medical Research Involving Subjects Act (WMO). The CCMO was created on the 6th of April 1999 and is based in The Hague, the Netherlands CCMO executes the WMO and the Embryo's Act. Research that falls under the WMO or the Embryo's Act must be reviewed by an independent committee of experts. Research is not allowed to start without a positive decision of this committee.[4,6]

Figure no. 3: CCMO Logo.

Organisation of CCMO

The organizational structure of CCMO of the CCMO is divided into two primary branches:

1. Committee Members
2. The Secretariat

1. Committee Members

The CCMO Committee Members serve as the governing and decision-making body of the organization. The committee and deputy members are appointed by the Minister of Health, Welfare and Sport for a four-year term. It consists of experts from various disciplines, including medical specialists, legal experts, ethicists, methodologists, and fundamental scientists. A Ministry of Health observer also attends the committee meetings. All members are expected to work independently and review research protocols without any conflict of interest.

2. The Secretariat

The CCMO Secretariat is managed by the Chief Executive Officer (CEO) and is responsible for the daily operations and administrative activities of the committee. It has four main departments: Legal Affairs and Supervision, which deals with legislation and monitoring accredited MRECs; Europe, which handles European and international clinical trial matters; the National Clinical Trial Office, which manages clinical trial applications and coordination; and Operational Management, which provides administrative and financial support.

Functions of CCMO

1. Reviews high-risk research such as gene therapy, vaccines, and cell therapy.
2. Accredits and supervises MRECs to ensure quality and independence.
3. Acts as a competent authority for clinical drug and medical device trials.
4. Handles appeals against negative MREC decisions.
5. Maintains the OMON register of approved medical research.[6]

REGULATORY FRAMEWORK FOR CLINICAL TRIALS IN INDIA

Regulatory approval in India is mainly governed by CDSCO under the DCGI, ensuring the safety, efficacy, and quality of drugs before marketing.

1. CDSCO: India's national regulatory authority responsible for new drug approvals, clinical trials, medical devices, imports, pharmacovigilance, and GMP compliance.
2. DCGI: Heads CDSCO and grants permissions for the manufacture, import, and marketing of new drugs, approves clinical trials, and monitors drug safety.
3. State Drug Control Authorities: Regulate the manufacture, licensing, distribution, and sale of drugs at the state level and prevent adulteration and misbranding.
4. NDCT Rules, 2019: The New Drugs and Clinical Trials Rules, 2019, introduced a unified framework to improve transparency, accountability, and timely regulatory approvals.
5. Regulatory Framework: NDCTR 2019 operates under the Drugs and Cosmetics Act, 1940 and provides comprehensive requirements for new drugs and clinical trials.[3]

REGULATORYFRAMEWORK FOR CLINICAL TRIALS IN NETHERLAND

The regulatory framework for conducting clinical trials in the Netherlands is highly streamlined, combining European Union-wide legislation with specific Dutch national laws and oversight bodies.

1. Prevention of medicine shortages.[5,6]

CLINICAL TRIAL APPROVAL PROCESS IN INDIA

The Indian pathway begins with trial preparation. The sponsor prepares a clinical-trial dossier containing the protocol and relevant scientific, clinical, manufacturing and participant-protection information. The project lists documents such as the Clinical Trial Protocol, Investigator's Brochure, Informed Consent Form, Case Report Form, preclinical reports, previous clinical data where available, investigator and site details, insurance/compensation documentation, Ethics Committee information and Chemistry, Manufacturing and Control data. The application is submitted electronically through the SUGAM portal. The project describes Form CT-04 as the application for permission to conduct a clinical trial of a new drug or investigational new drug, together with supporting documents and prescribed fees. CDSCO conducts an administrative screening to check completeness and may raise queries requiring clarification or additional information.

Ethical review is conducted by a registered Ethics Committee. The review considers scientific validity, participant safety, risk-benefit balance, informed consent, vulnerable populations, investigator qualifications and site suitability. The project also notes that parallel submission and processing can support coordination between CDSCO and Ethics Committees.

CDSCO then performs scientific and technical review. Areas include the quality of the investigational product, non-clinical safety data, clinical rationale, trial design, methodology, statistical considerations and overall risk-benefit assessment. Following review and resolution of deficiencies, the regulatory authority may approve, approve with conditions, request additional information or reject the application. The project identifies Form CT-06 as the permission form described in its pathway. Trial initiation occurs only after the required approvals have been obtained.

After initiation, the sponsor and investigator must follow the approved protocol and GCP requirements. Safety events must be reported as required, monitoring must continue, and amendments or other regulatory changes must be managed through the applicable process. At completion, the sponsor prepares the Clinical Study Report and submits end-of-study information.[3]

CLINICAL TRIAL APPROVAL PROCESS IN NETHERLANDS

The Dutch approval process starts with preparation of a complete clinical-trial application. The project identifies documents such as the protocol, Investigator's Brochure, Investigational Medicinal Product Dossier, informed-consent documents, insurance certificate, investigator information, recruitment materials, budget and agreements, and data-management information.Once submitted through CTIS, the application undergoes validation. The scientific assessment examines the scientific rationale, methodology, risk-benefit balance, quality and safety of the investigational medicinal product and other required elements. The assessment is conducted according to the EU CTR framework and may involve multiple Member States when a multinational trial is concerned.

Ethical and national assessment considers participant information and informed consent, protection of participants, insurance and indemnity, recruitment, local feasibility and other national requirements. In the Netherlands, an accredited MREC or the CCMO performs the relevant ethics review depending on the study.

The project describes the Dutch site-suitability process and the VGO (Verklaring Geschiktheid Onderzoeksinstelling) as a mechanism for documenting institutional suitability. This illustrates an important principle: regulatory authorization alone does not automatically mean that every trial site is operationally ready. Institutional capacity, staffing, facilities and local arrangements must also be addressed.

Possible regulatory outcomes include authorization, authorization with conditions, a request for information, or rejection. Once the required decision and site arrangements are in place, the trial can begin. Investigators must be trained, the site activated and participant recruitment conducted according to the approved protocol.

During conduct, GCP compliance, quality assurance, safety monitoring and protocol compliance remain essential. Safety information includes serious adverse events and suspected unexpected serious adverse reactions, with reporting according to the applicable EU requirements. Annual safety information and other required reports support continuing risk assessment.

At completion, end-of-trial information and the Clinical Study Report are prepared. Results are submitted through the applicable systems, and public transparency requirements support dissemination of trial information.[5]

REGULATORY INSPECTION AND COMPLIANCE SYSTEM

Regulatory approval is only the beginning of clinical-trial oversight. Sponsors and investigators must demonstrate continuing compliance with the approved protocol, GCP, applicable legislation and safety requirements. Inspections provide an independent assessment of whether trial activities and documentation meet regulatory expectations.In India, the project describes inspection and monitoring in relation to CDSCO/CLA and compliance with NDCTR 2019 and Indian GCP requirements. Inspections may examine trial sites and other regulated entities. Areas of interest include participant records, informed consent,

investigational-product accountability, source documentation, protocol compliance, safety reporting, data integrity and essential trial documents.

In the Netherlands, inspection and supervision operate under the EU/Dutch framework. The project identifies IGJ as the relevant inspection authority and describes a focus on participant protection, reliability of clinical-trial results and compliance with EU CTR, WMO and GCP requirements.[1,6]

COMPARATIVE ANALYSIS OF INDIA AND NETHERLANDS

The central difference is regulatory architecture. India primarily uses a national system centered on CDSCO and the NDCTR 2019 framework. The Netherlands uses the EU CTR and CTIS while applying Dutch national legislation and relying on national authorities and accredited ethics committees.Application systems also differ. India uses SUGAM for relevant clinical-trial submissions. The Netherlands uses CTIS for medicinal-product clinical-trial applications under the EU CTR. CTIS is designed to support multinational studies and combines regulatory workflow with public transparency.

Ethics review is mandatory in both systems, but the institutional arrangements differ. India uses registered Institutional/Independent Ethics Committees within the national framework. The Netherlands uses accredited MRECs/METCs and the CCMO according to the type and legal category of research.

Trial registration and transparency are structured differently. India uses CTRI for public registration, while the Netherlands and EU use CTIS public disclosure, with Dutch research information also consolidated through OMON. The European approach is especially useful for multinational trials because information and assessment operate within a harmonized system.

Scientific assessment is also organized differently. Indian applications are reviewed by CDSCO and may be referred to Subject Expert Committees. Under the EU CTR, assessment is organized into common EU and national components. This division can reduce duplication for multinational studies but requires sponsors to understand both EU-level and Dutch national requirements.

Participant protection is a common priority. Both systems require informed consent, ethical review, safety reporting, GCP compliance and continuing oversight. India has detailed national provisions for compensation for trial-related injury/death. The Netherlands relies on Dutch/EU legal and insurance arrangements for participant protection.

Neither system should be described as universally 'better'. Their differences reflect different governance structures. India's national model can provide a clear central route for studies conducted in India; the Dutch/EU model offers harmonization for multinational European trials and extensive public transparency.[7]

Table no 3: Comparative Analysis of India and Netherlands.

Parameter	India	Netherlands/EU
Primary framework	NDCTR 2019	EU CTR 536/2014 + Dutch WMO
Main submission	SUGAM	CTIS
Ethics	Registered Ethics Committee	Accredited MREC/METC or CCMO
Medicines authority	CDSCO/CLA	MEB/CBG-MEB within EU framework
Inspection	CDSCO/CLA	IGJ and EU/Dutch framework
Registration/transparency	CTRI + regulatory information	CTIS + OMON
Multinational trials	Separate Indian compliance	Harmonized EU mechanism

CONCLUSION

The study compared the clinical trial regulatory systems of India and the Netherlands, with both countries focusing on scientific validity, ethical conduct, participant safety, and reliable data.InIndia clinical trials are regulated mainly by CDSCO under NDCTR 2019, with applications submitted through the SUGAM portal and reviewed by regulatory and Ethics Committees. Safety monitoring and compensation for trial-related injuries are important requirements.InNetherlands clinicaltrials follow the EU Clinical Trials Regulation (EU CTR 536/2014) and use CTIS for centralized submission and transparency. Ethical review is conducted by the CCMO or accredited MRECs.InComparison India follows a mainly national regulatory system, while the Netherlands operates within a harmonized European framework.Overallboth systems support safe and ethical clinical research. India could further improve digitalization, transparency, risk-based monitoring, and coordination among regulatory bodies.

ACKNOWLEDGEMENT

We would also like to express our deep gratitude and indebtedness guidance of all of our dynamic and

motivating teachers and our esteemed Principal **Dr. Suresh V Kulkarni.**The completion of this project would not have been possible without the assistance and the endless support of our Mentor, **Dr. P. Ashok Kumar,** M.Pharm, Ph.D., Professor, Department of Regulatory Affairs. We are sincerely thankful for your encouragement and kind supervision.The administrators and staff of Sree Siddaganga College of Pharmacy in Tumkur, Karnataka, are appreciated by the authors for providing the space needed to conduct.

REFERENCE

1. Central Drugs Standard Control Organisation. (n.d.). CDSCO. Retrieved August 28, 2026. Available from: URL: https://www.cdsco.gov.in/opencms/opencms/en/Acts-and-rules/New-Drugs/
2. Clinical trial application. (n.d.). CCMO. Retrieved August 28, 2026. Available from: URL: https://english.ccmo.nl/investigators/clinical-trials-with-medicinal-products-ctr/clinical-trial-application-ctr-from-start-to-finish
3. New drug approval information. (n.d.). CDSCO. Retrieved August 28, 2026. Available from: URL: https://cdsco.gov.in/opencms/opencms/en/Drugs/New-Drugs/
4. Application in the Netherland. (n.d.). CCMO. Retrieved August 28, 2026. Available from: URL: https://english.ccmo.nl/investigators/clinical-trials-with-medicinal-products-ctr/preparation-ctr/national-or-multinational/full-or-staggered-application-in-the-netherlands
5. Clinical trial application. (n.d.). CCMO. Retrieved August 28, 2026. Available from: URL: https://english.ccmo.nl/investigators/clinical-trials-with-medicinal-products-ctr/preparation-ctr/national-or-multinational/one-research-file-part-i-and-part-ii
6. EU Clinical Trial Regulation. (n.d.). CCMO. Retrieved August 28, 2026. Available from: URL: https://english.ccmo.nl/investigators/clinical-trials-with-medicinal-products-ctr/legal-framework-ctr
7. Kandi V, Vadakedath S. Clinical Trials and Clinical Research: A Comprehensive Review. Cureus, February 16, 2023; 15(2): e35077. DOI10.7759/cureus.35077. Available from: URL: [https://doi.org/10.7759/cureus.35077]